

## S 4152

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** May 5, 2022

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 5, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/4152>

### Sponsor

**Name:** Sen. Kelly, Mark [D-AZ]

**Party:** Democratic • **State:** AZ • **Chamber:** Senate

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Collins, Susan M. [R-ME]	R · ME		May 5, 2022
Sen. Sinema, Kyrsten [D-AZ]	D · AZ		May 5, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 5, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 HR 7658	Identical bill	May 3, 2022: Referred to the House Committee on Energy and Commerce.

### Summary (as of May 5, 2022)

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

### Actions Timeline

- **May 5, 2022:** Introduced in Senate
- **May 5, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.